References

1. 1. Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: Results of the TITAN Trial. Eur J Heart Fail. 2012;14(8):931–8. https://pubmed.ncbi.nlm.nih.gov/22613584/
   2. Gheorghe LL, Rojas SV, Botha P, Delgado V, Bax JJ. Imaging for native mitral valve surgical and transcatheter interventions. JACC Cardiovasc Imaging. 2021;14(1):112–27. https://www.mitralvalverepair.org/imaging-native-mitral-valve-surgical-and-transcatheter-interventions
   3. Giallauria F, Polimeni A, Arendar I, Lipiecki J, Siminiak T, Reuter DG, et al. Individual patient data meta-analysis of the effects of the Carillon® mitral contour system. ESC Heart Fail. 2020;7(6):3383–91. doi:10.1002/ehf2.13125. https://pubmed.ncbi.nlm.nih.gov/34351074/
   4. Braemswig TB, Bettencourt N, Faustino A, Ribeiro J, Gonçalves L, Silva JC, et al. Cerebral embolisation during transcatheter edge-to-edge repair of the mitral valve with the MitraClip system: a prospective, observational study. EuroIntervention. 2022;18(2):e160–8. doi:10.4244/EIJ-D-21-00646. https://pubmed.ncbi.nlm.nih.gov/34916177/
   5. O’Brien B, Zafar H, Khan J, Keaney JJ, Coffey S, Kiernan TJ. Transseptal puncture—review of anatomy, techniques, complications and challenges. Int J Cardiol. 2017;233:12–22. doi:10.1016/j.ijcard.2017.02.009. https://pubmed.ncbi.nlm.nih.gov/28202256/
   6. Forlani D, Esposito G, Faggiano P, Bursi F, Agricola E, Tarantini G, et al. Indirect mitral annuloplasty using the Carillon Contour System: single center experience. Eur Heart J Suppl. 2022;24(Suppl_C):suac011.033. doi:10.1093/eurheartj/suac011.033. https://academic.oup.com/eurheartjsupp/article/24/Supplement_C/suac011.033/6587696
   7. Stark K, Mossberg S. Standards in oral anticoagulation after percutaneous valve intervention. Aktuel Kardiol. 2022;11:477–83. https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1911-4911?
   8. Chhatriwalla AK, Vemulapalli S, Szerlip M, Dai D, Sorajja P, Kar S, et al. Operator experience and outcomes of transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2019;74(24):2955–65. doi:10.1016/j.jacc.2019.09.014. https://www.jacc.org/doi/10.1016/j.jacc.2019.09.014?
   9. Al-Azizi K, Szerlip M. Mitral stenosis after MitraClip: how to avoid and how to treat. Curr Cardiol Rep. 2020;22(7):50. doi:10.1007/s11886-020-01301-5. https://pubmed.ncbi.nlm.nih.gov/32500412/

   10. McDonagh TA, Schulze PC, Abdelhamid M, Aboyans V, Adamopoulos S, Anker SD, Arbelo E, Asteggiano R, Bauersachs J, Bayes‑Genis A, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure?

   11. Abbott. MitraClip Instructions for Use. EL2204011. 2020 Jul 22.
   12. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, et al. Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation. Eur J Heart Fail. 2021;23(11):1971–8. doi:10.1002/ejhf.2310. https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.2310?
   13. Anker SD, Butler J, Filippatos G, Lam CSP, Abraham WT, Ponikowski P, et al. Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation and severe left ventricular enlargement. JACC Heart Fail. 2021;9(6):453–62. doi:10.1016/j.jchf.2021.03.002. https://www.sciencedirect.com/science/article/pii/S2213177921001207?
   14. Stone GW. A randomized trial of transcatheter mitral valve leaflet approximation in patients with heart failure and secondary mitral regurgitation. Presented at: TCT 2018; 2018 Sep; San Diego, CA. https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=91cb486e6df44236bcf58b891db378c1
   15. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, et al. The REDUCE FMR Trial: A randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation. JACC Heart Fail. 2019;7(11):945–55. doi:10.1016/j.jchf.2019.06.011. https://www.jacc.org/doi/10.1016/j.jchf.2019.06.011?
   16. Cardiac Dimensions. Carillon Mitral Contour System® Instructions for Use. Kirkland, WA: Cardiac Dimensions; 2023 Jul 27.
   17. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med.  2018;379(24):2307–18. doi:10.1056/NEJMoa1806640. https://www.nejm.org/doi/full/10.1056/NEJMoa1806640?
   18. Lipiecki J, Siminiak T, Sievert H, Müller-Ehmsen J, Degen H, Wu JC, et al. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. Open Heart. 2016;3(2):e000411. doi:10.1136/openhrt-2016-000411. https://openheart.bmj.com/content/3/2/e000411?
   19. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med.  2018;379(24):2297–306. doi:10.1056/NEJMoa1805374.https://www.nejm.org/doi/full/10.1056/NEJMoa1805374?
   20. Rottländer D, Figulla HR, Kuck KH, Zahn R, Sievert H, Butter C, et al. Percutaneous coronary sinus–based mitral valve annuloplasty in atrial functional mitral regurgitation. JACC Cardiovasc Interv. 2020;13(24):2947–9. doi:10.1016/j.jcin.2020.09.052. https://www.jacc.org/doi/10.1016/j.jcin.2020.09.019?
   21. Lipiecki J, Siminiak T, Witte K, Goldberg SL, Reuter DG, Haude M, et al. Long-term survival following transcatheter mitral valve repair: pooled analysis of prospective trials with the Carillon device. Cardiovasc Revasc Med. 2020;21(6):712–6.doi:10.1016/j.carrev.2020.02.012.https://pubmed.ncbi.nlm.nih.gov/32111559/
   22. Witte KK. New results from the CINCH-FMR Post-Market Registry: treatment of heart failure patients with functional mitral regurgitation with the Carillon Mitral Contour System. Presented at: THT 2025; 2025 Mar; Boston, MA. Symposium presentation. https://cardiacdimensions.com/wp-content/uploads/pubs/THT_2025_%20CINCH.pdf
   23. Priebe-Brämer M. 200+ patients, real-world impact: Carillon therapy in routine care. Presented at: THT 2025; 2025 Mar; Boston, MA. Symposium presentation. https://cardiacdimensions.com/200-patients-real-world-impact-carillon-therapy-in-routine-care/
   24. Mayo Clinic. Mitral valve regurgitation. Mayo Clinic; 2023 Sep 19. Available from: https://www.mayoclinic.org/diseases-conditions/mitral-valve-regurgitation

   25. Stöbe S et al.; Echocardiographic analysis of acute effects of percutaneous mitral annuloplasty on severity of secondary mitral regurgitation; ESC Heart Fail. 2020 Aug; 7(4): 1645–1652. https://pmc.ncbi.nlm.nih.gov/articles/PMC7373905/

   26. Witte KK, Kaye DM, Lipiecki J, Siminiak T, Goldberg SL, von Bardeleben RS, et al. Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation. Eur J Heart Fail. 2021;23(11):1971-8. doi:10.1002/ejhf.2310. https://pmc.ncbi.nlm.nih.gov/articles/PMC7373905/
   27. Kałmucki P, Lipiecki J, Dankowski R, Witte KK, Baszko A, Starling RC, Siminiak T. Improvement in echocardiographic mitral regurgitation parameters correlates with left ventricular reverse remodeling after percutaneous mitral annuloplasty. Pol Heart J. 2025;83(7):725-733. doi:10.33963/v.phj.105726. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37516263
   28. Seidel et al. – Draft manuscript
   29. Khan MS, Siddiqi TJ, Butler J, et al. Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial. ESC Heart Fail. 2021;8(2):872-878. doi:10.1002/ehf2.13273. https://pubmed.ncbi.nlm.nih.gov/33619896/
   30. Fichtlscherer S, Hicea S, Barbieri F, et al. Long-Term Outcomes of Indirect Annuloplasty for Functional Mitral Regurgitation: Interim Results From the CINCH Registry. Struct Heart. 2025;9(12):100738. Published 2025 Oct 12. doi:10.1016/j.shj.2025.100738. https://pmc.ncbi.nlm.nih.gov/articles/PMC12666833/
   31. Priebe-Brämer H, Jaly F, Rahunathan N, et al. Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience. ESC Heart Fail. 2025;12(6):4410-4418. doi:10.1002/ehf2.70016. https://pmc.ncbi.nlm.nih.gov/articles/PMC12719853/
   32. Schofer J, Siminiak T, Haude M, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation. 2009;120(4):326-333. doi:10.1161/CIRCULATIONAHA.109.849885. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.849885
   33. Khan MS, Friede T, Anker SD, Butler J. Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. ESC Heart Fail. 2021;8(3):1885-1891. doi:10.1002/ehf2.13301. https://pubmed.ncbi.nlm.nih.gov/33784028/
   34. Rottländer D, Golabkesh M, Degen H, Ögütcü A, Saal M, Haude M. Mitral valve edge-to-edge repair versus indirect mitral valve annuloplasty in atrial functional mitral regurgitation. Catheter Cardiovasc Interv. 2022;99(6):1839-1847. doi:10.1002/ccd.30157. https://europepmc.org/article/MED/35312231
   35. Ruf TF, Kreidel F, Tamm AR, et al. Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secondary mitral regurgitation. ESC Heart Fail. 2020;7(4):1400-1408. doi:10.1002/ehf2.12710. https://pmc.ncbi.nlm.nih.gov/articles/PMC7373883/
   36. Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635-4736. doi:10.1093/eurheartj/ehaf194. https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/valvular-heart-disease/
   37. Sievert, H. 2018. REDUCE-FMR: A Sham Controlled Randomized Trial of Transcatheter Indirect Mitral Annuloplasty in Heart Failure Patients with Functional Mitral Regurgitation. Presented at TCT 2018, San Diego, CA. https://www.jacc.org/doi/10.1016/j.jchf.2019.06.011
   38. Lipiecki J, Kalmucki P, Miller LE, Durel N. Ten-year survival after indirect mitral annuloplasty with the Carillon Mitral Contour System in functional mitral regurgitation. A single-center followup from the REDUCE-FMR trial. Global Cardiol [Internet]. 2026 Jun. 26;4(2). Available from: https://www.globalcardiology.info/site/article/view/106
   39. Yildiz M, Haude M, Sievert H, et al. The CINCH-FMR postmarket registry: Real-world long-term outcomes with percutaneous mitral valve repair with the Carillon Mitral Contour System. Cardiovasc Revasc Med. 2024;60:35-40. doi:10.1016/j.carrev.2023.09.007. https://www.sciencedirect.com/science/article/abs/pii/S155383892300828X
   40. Abbott. Mitraclip G5 Instructions for Use. EL2144114 (2025-08-14)
   41. Gössl M, Sorajja P. MitraClip patient selection: inclusion and exclusion criteria for optimal outcomes. Ann Cardiothorac Surg. 2018;7(6):771-775. doi:10.21037/acs.2018.08.04; https://pmc.ncbi.nlm.nih.gov/articles/PMC6288214/
   42. Lo Russo G et al. Breaking the Barriers: Transseptal Puncture in Patients with Atrial Septal Defect Closure Devices. Interv Cardiol. 2025;20:e33. Published 2025 Dec 1. doi:10.15420/icr.2025.08; https://pmc.ncbi.nlm.nih.gov/articles/PMC12728519/
   43. Sherif MA, Paranskaya L, Yuecel S, et al. MitraClip step by step; how to simplify the procedure. Neth Heart J. 2017;25(2):125-130. doi:10.1007/s12471-016-0930-7; https://pmc.ncbi.nlm.nih.gov/articles/PMC5260622/
   44. Chizner R, Maini B, Bethea B, Patton M. Transjugular transcatheter mitral valve repair with MitraClip. Structural Heart. 2018;2(5):473–475. doi:10.1080/24748706.2018.1487613.; https://www.sciencedirect.com/science/article/pii/S2474870622002160
   45. https://clinicaltrials.gov/study/NCT03142152
   46. https://pubmed.ncbi.nlm.nih.gov/?term=carillon%20mitral&page=8
   47. Goldberg S et al.: Interim Results of the CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation (FMR) With the Carillon Mitral Contour System, Poster Presentation, TCT 2022; The Detrimental Impact of Chronic Renal Insufficiency
   48. Lipiecki J, Fahrat H, Monzy S, et al. Long-term prognosis of patients treated by coronary sinus-based percutaneous annuloplasty: single centre experience. ESC Heart Fail. 2020;7(6):3329-3335. doi:10.1002/ehf2.12955; Long‐term prognosis of patients treated by coronary sinus‐based percutaneous annuloplasty: single centre experience – PMC
   49. Rodés-Cabau J, Mengi S, Salaun E, Paradis JM, Abraham WT. Transcatheter edge-to-edge repair in secondary mitral regurgitation. EuroIntervention. 2025;21(24):e1458-e1478. Published 2025 Dec 15. doi:10.4244/EIJ-D-25-00116; Transcatheter edge-to-edge repair in secondary mitral regurgitation | EuroIntervention
   50. Gheorgiade M et al.; Pathophysiologic targets in the early phase of acute heart failure syndromes. The American journal of cardiology, 2005 (6), 11-17.
   51. Ahmed A et al.; Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. American heart j 2006, 151(2), 444-450.
   52. Gheorghiade, M., & Pang, P. S.; Acute heart failure syndromes. JACC 2009, 53(7), 557-573.
   53. Holland, R. et al.; Patients’ self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J card fail 2010, 16(2), 150-156.
   54. Muntwyler, J. et al.; One-year mortality among unselected outpatients with heart failure. Eur Heart J 2002, 23(23), 1861-1866.
   55. Sannino A, Smith RL 2nd, Schiattarella GG, Trimarco B, Esposito G, Grayburn PA. Survival and Cardiovascular Outcomes of Patients With Secondary Mitral Regurgitation: A Systematic Review and Meta-analysis. JAMA Cardiol. 2017;2(10):1130-1139. doi:10.1001/jamacardio.2017.2976; https://jamanetwork.com/journals/jamacardiology/fullarticle/2652884
   56. Kałmucki P, Jerzykowska O, Dankowski R, et al. Percutaneous Trans-Coronary Venous Mitral Annuloplasty in Patients With Functional Mitral Regurgitation: Analysis of Poznan Carillon Registry Data. J Interv Cardiol. 2016;29(6):632-638. doi:10.1111/joic.12349; https://onlinelibrary.wiley.com/doi/epdf/10.1111/joic.12349
   57. Jerzykowska O, Kałmucki P, Wołoszyn M, Smuszkiewicz P, Firek L, Siminiak T. Echocardiographic evaluation of percutaneous valve repair in patients with mitral regurgitation using the CARILLON system. Kardiol Pol. 2010;68(1):57-63.
   58. Carlhäll C, Wigström L, Heiberg E, Karlsson M, Bolger AF, Nylander E. Contribution of mitral annular excursion and shape dynamics to total left ventricular volume change. Am J Physiol Heart Circ Physiol. 2004 Oct ;287(4):H1836-H1841. doi: 10.1152/ajpheart.00103.2004; https://journals.physiology.org/doi/full/10.1152/ajpheart.00103.2004
   59. Topilsky Y, Vaturi O, Watanabe N, et al. Real-time 3-dimensional dynamics of functional mitral regurgitation: a prospective quantitative and mechanistic study. J Am Heart Assoc. 2013;2(3):e000039. Published 2013 May 31. doi:10.1161/JAHA.113.000039; Real‐Time 3‐Dimensional Dynamics of Functional Mitral Regurgitation: A Prospective Quantitative and Mechanistic Study | Journal of the American Heart Association
   60. O’Gara PT, Grayburn PA, Badhwar V, et al. 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(19):2421–2449. doi:10.1016/j.jacc.2017.09.019; https://www.jacc.org/doi/10.1016/j.jacc.2017.09.019
   61. Acker MA, Bolling S, Shemin R, et al. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg. 2006;132(3):568-577.e5774. doi:10.1016/j.jtcvs.2006.02.062; https://www.jtcvs.org/article/S0022-5223(06)00887-7/abstract
   62. Haan CK, Cabral CI, Conetta DA, Coombs LP, Edwards FH. Selecting patients with mitral regurgitation and left ventricular dysfunction for isolated mitral valve surgery. Ann Thorac Surg 2004;78:820–5.
   63. Bax JJ, Braun J, Somer ST, et al. Restrictive annuloplasty and coronary revascularization in ischemic mitral regurgitation results in reverse left ventricular remodeling. Circulation. 2004;110(11 Suppl 1):II103-II108. doi:10.1161/01.CIR.0000138196.06772.4e; https://www.ahajournals.org/doi/10.1161/01.CIR.0000138196.06772.4e
   64. Harris KM, Sundt TM 3rd, Aeppli D, Sharma R, Barzilai B. Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve?. Ann Thorac Surg. 2002;74(5):1468-1475. doi:10.1016/s0003-4975(02)03920-6: https://www.annalsthoracicsurgery.org/article/S0003-4975(02)03920-6/fulltext
   65. Amigoni M, Meris A, Thune JJ, et al. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: Prognostic significance and relation to ventricular size and function. European Heart J 2007; 28:326-333
   66. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-2150. doi:10.1056/NEJMoa032423; https://www.nejm.org/doi/10.1056/NEJMoa032423
   67. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:1845-53; https://www.nejm.org/doi/10.1056/NEJMoa013168
   68. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56(5):392-406. doi:10.1016/j.jacc.2010.05.011; https://www.jacc.org/doi/10.1016/j.jacc.2010.05.011

Cardiac Dimensions, Carillon and Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions, PTY LTD. The Carillon Mitral Contour System has received CE Mark approval (0344) and is available for sale in the European Union. CAUTION: The Carillon Mitral Contour System is limited to investigational use in the United States.